l***d
发帖数: 1828 | 1 生理学或医学
Brian J. Druker 美国奥勒冈州波特兰市奥勒冈健康暨科学大学 (Oregon Health
Science University)医学教授、JELD-WEN血癌研究教授及奈特癌症研究所(OHSU
Knight Cancer Institute)主任、同时也是霍尔休斯医学研究所(Howard Hughes
Medical Institute)研究人员
Nicholas B. Lydon 美国怀俄明州杰克森洞(Jackson Hole, WY)Granite ***a, LLC
创办人；美国加州圣地牙哥AnaptysBio共同创办人兼总监；及美国麻州剑桥Blueprint
Medicines共同创办人兼总监
Charles L. Sawyers 美国纽约州纽约市Memorial Sloan-Kettering癌症中心人类肿
瘤学及病因Marie-Josee and Henry R. Kravis教授、同时也是霍尔休斯医学研究所(
Howard Hughes Medical Institute)研究人员
获奖成就：他们发展出***性慢性骨髓性白血病治疗药物imatinib 及 dasatinib
(英文原文：For their development of imatinib and dasatinib, revolutionary,
targeted treatments for chronic myeloid leukemia)
Robert S. Langer 美国麻州剑桥麻省理工学院(Massachusetts Institute of
Technology)化工系David H. Koch Institute教授
Joseph P. Vacanti 哈佛医学院(Harvard Medical School)John Homans外科教授；
美国麻州波士顿麻州综合医院(Massachusetts General Hospital)首席外科医师兼小儿
外科主任及组织工程暨器官构造实验室主任
获奖成就：他们在组织工程及再生医学方面的先驱研究
(英文原文：For their pioneering research in tissue engineering and
regenerative medicine)
Jacques F. A. P. Miller 澳洲墨尔本帕克维尔墨尔本大学医学研究所(Walter and
Eliza Hall Institute of Medical Research)暨墨尔本大学(University of
Melbourne)荣誉教授
获奖成就：发现胸腺的功能并在哺乳类动物身上找到T细胞与B细胞
(英文原文：For his discovery of the function of the thymus and the
identification of T cells and B cells in mammalian species)
Robert L. Coffman 美国加州柏克莱Dynavax Technologies副总兼科学长
Timothy R. Mosmann 美国纽约州罗彻斯特市罗彻斯特大学(University of
Rochester)微生物学与免疫学系教授、及罗彻斯特大学医学中心疫苗生物学与免疫学
David H. Smith中心Michael and Angela Pichichero主任
获奖成就：他们发现TH1及TH2两种T淋巴细胞、以及它们在调节宿主免疫应答上的角色
化学
Allen J. Bard 美国德州大学奥斯丁分校(University of Texas at Austin)之化
学与生物化学学院，化学系Hackerman-Welch Regents教授兼电化学中心主任
获奖成就：扫瞄电化学显微术的发展与应用
(英文原文：For the development and application of scanning electrochemical
microscopy)
Martin Karplus 美国麻州剑桥哈佛大学(Harvard University, Cambridge)化学暨
化学生物系Theodore William Richards化学荣誉教授、法国史特拉斯堡路易巴斯德大
学(Louis Pasteur University)科学与超分子工程研究院(ISIS)生物物理化学实验室主任
获奖成就：生物分子的分子动态先驱模拟
(英文原文：For pioneering simulations of the molecular dynamics of
biomolecules)
Jean M. J. Frechet 美国加州柏克莱大学(University of California Berkeley,)
化学系化学及化工教授兼Henry Rapoport有机化学教授、沙乌地阿拉伯图沃阿布都拉国
王科技大学(King Abdullah University of Science and Technology)研究副校长
Donald A. Tomalia 美国密西根州欢喜山中密西根大学(Central Michigan
University)化学系杰出教授兼研究科学家及国家树状分子与奈米科技中心(National
Dendrimer and Nanotechnology Center)主任、同时也是美国密西根州欢喜山(
Dendritic Nanotechnologies, Inc)科学长
Fritz Vogtle 德国波昂市波昂大学(Rheinische Friedrich-Wilhelms-Universitat
Bonn)有机化学与生物化学科库尔研究院(Kekule Institute for Organic Chemistry
and Biochemistry)荣誉教授
获奖成就：树形聚合物的发明与发展
(英文原文：For the invention and development of dendritic polymers)
物理学
Alain Aspect 法国国家研究(CNRS)院杰出科学家及法国帕拉索光学研究所(
Institut d'Optique, Palaiseau France)Charles Fabry实验室原子光学群(Atom
Optics Group)主管、同时也是法国光学研究所(Institut d’Optique)及综合理工学院
(Ecole Polytechnique)教授
John F. Clauser 美国加州核桃溪J.F. Clauser & Associates研究物理学家
Anton Zeilinger 维也纳大学(University of Vienna)实验物理学全职教授、奥地
利维也纳奥地利科学研究院(Austrian Academy of Sciences)量子光学及量子资讯研究
院科学主任
获奖成就：他们对Bell's inequalities的检验及在quantum entanglement方面的研究
(英文原文： For their tests of Bell’s inequalities and research on quantum
entanglement)
Sajeev John 加拿大安大略多伦多市多伦多大学(University of Toronto)物理学系
大学物理学教授暨加拿大研究教授
Eli Yablonovitch 美国加州柏克莱大学(University of California Berkeley)电
机与计算机科学系教授兼James and Katherine Lau工程教授
获奖成就：他们对photonic band gap materials的发现和发展
(英文原文：For their invention and development of photonic band gap
materials)
Hideo Ohno 日本仙台东北大学(Tohoku University)电子通讯研究所奈米电子及自
旋电子学教授、及自旋电子整合系统中心主任
获奖成就：对稀磁性半导体中的铁磁性之贡献 | l***d
发帖数: 1828 | 2 To be honest, I think none of them will receive nobel prize in medicine this
year. | h******y
发帖数: 1374 | | i****g
发帖数: 3896 | 4 这个根据citation的预测一直就不怎么准 好像发给临床的成果从来没预测到过？
LLC
Blueprint
【在 l***d 的大作中提到】
: 生理学或医学
: Brian J. Druker 美国奥勒冈州波特兰市奥勒冈健康暨科学大学 (Oregon Health
: Science University)医学教授、JELD-WEN血癌研究教授及奈特癌症研究所(OHSU
: Knight Cancer Institute)主任、同时也是霍尔休斯医学研究所(Howard Hughes
: Medical Institute)研究人员
: Nicholas B. Lydon 美国怀俄明州杰克森洞(Jackson Hole, WY)Granite ***a, LLC
: 创办人；美国加州圣地牙哥AnaptysBio共同创办人兼总监；及美国麻州剑桥Blueprint
: Medicines共同创办人兼总监
: Charles L. Sawyers 美国纽约州纽约市Memorial Sloan-Kettering癌症中心人类肿
: 瘤学及病因Marie-Josee and Henry R. Kravis教授、同时也是霍尔休斯医学研究所(
| A******y
发帖数: 2041 | 5 Druker will win one day because he conquered a disease (may not be this year
), plus the study published in NEJM this year further states the important
of his discovery. | n*********b
发帖数: 140 | 6 If the Nobel committee wants to award the target therapy for CML, they need
to figure out how to award both Peter Nowell and Janet Rowley and possibly
others whose contributions not only help the discovery of Gleevec but also
cancer genetics. The Lasker Foundation has grouped the two with Knudson,
which could be one followed by another one to target therapy.
year
【在 A******y 的大作中提到】
: Druker will win one day because he conquered a disease (may not be this year
: ), plus the study published in NEJM this year further states the important
: of his discovery.
| l********g
发帖数: 19 | 7 How about the works in the basic science in this area, like Owen Witte and
David Baltimore on the Ableson kinase, or Tony Hunter and Tony Pawson in
tyrosine phosphorylation in general, etc? If we are talking about a
discovery.
need
【在 n*********b 的大作中提到】
: If the Nobel committee wants to award the target therapy for CML, they need
: to figure out how to award both Peter Nowell and Janet Rowley and possibly
: others whose contributions not only help the discovery of Gleevec but also
: cancer genetics. The Lasker Foundation has grouped the two with Knudson,
: which could be one followed by another one to target therapy.
:
: year
| n*********b
发帖数: 140 | 8 Yes, the others include Owen Witte and Baltimore for their work on the
mechanistic insight of the ABL family.
Between Rowley's discovery and their work, there was a discovery of the BCR-
ABL fusion transcript that has clearly revealed the presence of the BCR-ABL
chimera protein. If Nobel goes to cancer genetics, these work may not be
credited together.
If Nobel goes to the illustration of posttranslational modification in
signal transduction or other aspects of physiology and medicine, their work
seems not as original as that of Hunter and Pawson. The pair has received
almost every award except Lasker and Nobel. | g*******f
发帖数: 427 | 9 我还以为发现TH1及TH2的早得奖了呢，照这个趋势看来，NKT, Th17 等等终有一天也会
得奖的。
Jacques F. A. P. Miller 澳洲墨尔本帕克维尔墨尔本大学医学研究所(Walter and
Eliza Hall Institute of Medical Research)暨墨尔本大学(University of
Melbourne)荣誉教授
获奖成就：发现胸腺的功能并在哺乳类动物身上找到T细胞与B细胞
这个还没得奖，为什么 Peter C. Doherty反而先得了? | j********r
发帖数: 156 | 10 Admiring the insights and knowledgeability of Needlescrub.
Which target do you think would revolutionize the cancer target therapy? | | | w**r
发帖数: 134 | 11 I like this prediction.
http://wavefunction.fieldofscience.com/2011/09/2011-nobel-prize
MEDICINE:
1. Nuclear receptors (Easy)
Pros: The importance of these proteins is unquestioned. Most predictors seem
to converge on the names of Chambon/Jensen/Evans.
2. Chaperones: (Easy)
Arthur Horwich and Franz-Ulrich Hartl just won this year's Lasker Award for
their discovery of chaperones. Their names have been high on the list for
some time now.
Pros: Clearly important. Chaperones are not only important for studying
protein folding on a basic level but in the last few years the
malfunctioning of chaperones such as heat-shock proteins has been shown to
be very relevant to diseases like cancer.
Cons: Too early? Probably not.
3. Statins (Difficult)
Akira Endo’s name does not seem to have been discussed much. Endo
discovered the first statin. Although this particular compound was not a
blockbuster drug, since then statins have revolutionized the treatment of
heart disease.
Pros: The “importance” as described in Nobel’s will is obvious since
statins have become the best-selling drugs in history. It also might be a
nice statement to award the prize to the discovery of a drug for a change.
Who knows, it might even boost the image of a much maligned pharmaceutical
industry...
Cons: The committee is not really known for awarding actual drug discovery.
Precedents like Alexander Fleming (antibiotics), James Black (beta blockers,
antiulcer drugs) and Gertrude Elion (immunosuppresants, anticancer agents)
exist but are far and few in between. On the other hand this fact might make
a prize for drug discovery overdue.
4. Genomics (Difficult)
A lot of people say that Venter should get the prize, but it’s not clear
exactly for what. Not for the human genome, which others would deserve too.
If a prize was to be given out for synthetic biology, it’s almost certainly
premature. Venter’s synthetic organisms from last year may rule the world,
but for now we humans still prevail. On the other hand, a possible prize
for genomics may rope in people like Carruthers and Hood who pioneered
methods for DNA synthesis.
5. DNA diagnostics and fingerprinting (Easy)
Now this seems to me to be very much a field from the "obvious" category.
The impact of DNA fingerprinting and Western and Southern Blots on pure and
applied science- everything from discovering new drugs to hunting down
serial killers- is at least as big as the prizeworthy PCR. I think the
committee would be doing itself a favor by honoring Jeffreys, Stark,
Burnette and Southern.
6. Stem Cells (Easy)
This seems to be yet another favorite. McCulloch and Till are often listed.
Unfortunately McCullough died earlier this year so it would be a little
unfair to award just Till. However such a thing is not unprecedented. For
example, the psychologist Daniel Kahneman shared the 2002 Economics Nobel
Prize with Vernon L. Smith. Left out was his long-time collaborator Amos
Tversky who had died in the 90s; it's pretty much regarded as a given that
Tversky would have shared the prize had he been alive.
Pros: Surely one of the most important biological discoveries of the last 50
years, promising fascinating advances in human health and disease.
Cons: Politically controversial (although we hope the committee can rise
above this). Plus, a 2007 Nobel was awarded for work on embryonic stem cells
using gene targeting strategies so there’s a recent precedent.
7. Membrane vesicle trafficking (Easy)
Rothman and Schekman
Pros: Clearly important. The last trafficking/transport prize was given out
in 1999 (Blobel) so another one is due and Rothman and Schekman seem to be
the most likely canidates. Plus, they have already won the Lasker Award
which in the past has been a good indicator of the Nobel.
8. GPCR structures (Difficult)
A commenter reminded me of this. When the latest GPCR structure (the first
one of a GPCR bound to a G protein) came out I remember remarking that
Kobilka, Stevens and Palczewski are probably up for a prize sometime.
Palczewski solved the first structure of rhodopsin and Stevens and Kobilka
have been churning out structure after important structure over the last
decade, including the first structure of an active receptor along with
several medicinally important ones including the dopamine D3 and CXCR4
receptors. These feats are definitely technical tour de forces.
Pros: GPCR's are clearly important for basic and applied science, especially
drug discovery where 30% of drugs already target these proteins.
Cons: Too early. | n*********b
发帖数: 140 | 12 It would be nice that Peter Nowell, Janet Rowley and Brian Druker can share
the price this year.
These three individuals have made most significant contributions to our
understanding of the molecular basis as well as targeted treatment for CML.
Given CML as a model, it should be easy to define targets in hematopoietic
malignancies and soft tissue sarcoma. It is difficult to name targets in
solid tumors since they usually involve multiple clones and each clone
harbors multiple mutations.
【在 j********r 的大作中提到】
: Admiring the insights and knowledgeability of Needlescrub.
: Which target do you think would revolutionize the cancer target therapy?
| z***k
发帖数: 33 | 13 To be fair, if Nobel picks something of "targeted therapy" in cancer, APL,
but not CML, should be the first to think about. Chinese should have a slot
here, too.
share
.
【在 n*********b 的大作中提到】
: It would be nice that Peter Nowell, Janet Rowley and Brian Druker can share
: the price this year.
: These three individuals have made most significant contributions to our
: understanding of the molecular basis as well as targeted treatment for CML.
: Given CML as a model, it should be easy to define targets in hematopoietic
: malignancies and soft tissue sarcoma. It is difficult to name targets in
: solid tumors since they usually involve multiple clones and each clone
: harbors multiple mutations.
| h******u
发帖数: 131 | | h******u
发帖数: 131 | | N*S
发帖数: 783 | 16 名单应该已经定了吧，会不会内部已经有人知道（比如说记者?)
LLC
Blueprint
【在 l***d 的大作中提到】
: 生理学或医学
: Brian J. Druker 美国奥勒冈州波特兰市奥勒冈健康暨科学大学 (Oregon Health
: Science University)医学教授、JELD-WEN血癌研究教授及奈特癌症研究所(OHSU
: Knight Cancer Institute)主任、同时也是霍尔休斯医学研究所(Howard Hughes
: Medical Institute)研究人员
: Nicholas B. Lydon 美国怀俄明州杰克森洞(Jackson Hole, WY)Granite ***a, LLC
: 创办人；美国加州圣地牙哥AnaptysBio共同创办人兼总监；及美国麻州剑桥Blueprint
: Medicines共同创办人兼总监
: Charles L. Sawyers 美国纽约州纽约市Memorial Sloan-Kettering癌症中心人类肿
: 瘤学及病因Marie-Josee and Henry R. Kravis教授、同时也是霍尔休斯医学研究所(
| j********r
发帖数: 156 | 17 It seems very likely that Nobel prize will be give to targeted therapy in
cancer.So far, the most successful example might just be the Gleevec-Sprycel
for CML. I do hope Nobel or Lasker will be given to arsenic trioxide/
retinoic, though which might not be a typical example of molecularly-
targeted therapy.
If certain drug can achieve the similar success in one type of solid cancer
as what anti-BCR-Able does in CML, that would be remarkable.
slot
【在 z***k 的大作中提到】
: To be fair, if Nobel picks something of "targeted therapy" in cancer, APL,
: but not CML, should be the first to think about. Chinese should have a slot
: here, too.
:
: share
: .
|
|
